Otsuka moves to broaden its neuropsychiatric portfolio with an acquisition of Transcend Therapeutics. The deal is valued at about $1.2 billion, including a $700 million upfront payment and up to $525 million in milestone consideration tied to development and commercial targets, with closing expected between April and the end of June.